Heart Failure With Preserved and Reduced Left Ventricular Ejection Fraction in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial | Zendy

Barry R. Davis | Zendy; John B. Kostis | Zendy; Lara M. Simpson | Zendy; Henry R. Black | Zendy; William C. Cushman | Zendy; Paula T. Einhorn | Zendy; Michael Färber | Zendy; Charles E. Ford | Zendy; Daniel Levy | Zendy; Barry M. Massie | Zendy; Shah Nawaz | Zendy

Open Access

Heart Failure With Preserved and Reduced Left Ventricular Ejection Fraction in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

Author(s) -

Barry R. Davis,

John B. Kostis,

Lara M. Simpson,

Henry R. Black,

William C. Cushman,

Paula T. Einhorn,

Michael Färber,

Charles E. Ford,

Daniel Levy,

Barry M. Massie,

Shah Nawaz

Publication year - 2008

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.107.762229

Subject(s) - medicine , doxazosin , lisinopril , chlorthalidone , cardiology , hazard ratio , ejection fraction , heart failure , amlodipine , confidence interval , blood pressure , angiotensin converting enzyme

Heart failure (HF) developing in hypertensive patients may occur with preserved or reduced left ventricular ejection fraction (PEF [>or=50%] or REF [<50%]). In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 42 418 high-risk hypertensive patients were randomized to chlorthalidone, amlodipine, lisinopril, or doxazosin, providing an opportunity to compare these treatments with regard to occurrence of hospitalized HFPEF or HFREF.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research